Kiniksa Pharmaceuticals International plc Class A (KNSA) — RQD Stock Rating Cockpit
Kiniksa Pharmaceuticals International plc Class A (KNSA) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (64/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+0.0% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
Warning: Paper profits outpaced real cash collected while unpaid invoices rose—classic earnings quality red flag.
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Our SEC fine-print scanner flagged elevated accounting or executive-hedging risk combined with interest-rate headwinds.
JEV AI Jury Split (Battleground) on KNSA
9.9% ROIC with 88.5% gross margin and 1.78% FCF yield.
Flagged cash-conversion divergence or elevated filing risk disclosures.
Put/Call 0.72x with 22/40 institutional & insider flow.
- ✓Strong cash generator (89% profit margin)—profits are backed by real money, not accounting tricks.
- !Headline earnings grew much faster than real operating cash flow—watch out for profit revisions.
- !Priced at 130x earnings—high expectations leave less room for a lukewarm quarter.
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring KNSA)
- ✓Live walkthrough of KNSA's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
KNSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +60.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KNSA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KNSA. Explore sector supply chains on /butterfly.
KNSA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell KNSA stock right now?
Kiniksa Pharmaceuticals International plc Class A (KNSA) currently earns a Roarable Rating of D+ (Sell — SELL) with 64/100 RQD Confidence. Accounting Warning: Paper earnings outpaced operating cash flow (+0.0% (NI vs OCF)) as receivables rose.
What is KNSA's 12-month price target and RQD AI Jury consensus?
KNSA's 12-month base price target is $100.19 (range $78.15 to $118.22), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.